You are here:

Archived: tadalafil (Adcirca)

Advice

in the absence of a submission from the holder of the marketing authorisation

tadalafil (Adcirca ®) is not recommended for use within NHS Scotland.

Indication under review: for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.
 

Drug Details

Drug Name: tadalafil (Adcirca)
SMC Drug ID: 710/11
Manufacturer: Lilly UK
Indication: For the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity.
BNF Category:
Sub Category: 2.5 Hypertension and heart failure
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 9 May 2011

Current Advice

Full submission 9 July 2012

Back